Paul Scherrer Institute

RaySearch Laboratories: Year-end report 2023

Retrieved on: 
Friday, February 23, 2024
Mass, Royal Marsden Hospital, Medical college, RaySearch Laboratories, Paul Scherrer Institute, Interim, Artemis, CBCT, Policy

RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.

Key Points: 
  • RaySearch secured an order from Israel-based P-Cure and expanded collaboration focusing on advanced proton therapy solutions.
  • The Royal Marsden in the UK will be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
  • Telephone: +46 (0)8 510 530 00, [email protected]
    Telephone: +46 (0)8 510 530 00, [email protected]
    The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act.
  • CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's year-end report for January-December 2023 at a webcast to be held in English on Friday, February 23, 2024 at 10:00-10:30 a.m. CET.

RaySearch Laboratories: Interim report January 1 - September 30, 2023

Retrieved on: 
Friday, November 17, 2023
Paul Scherrer Institute, CFO, Mass, Cyberknife, CET, University Medical Center Groningen, RaySearch Laboratories, Lausanne University Hospital, University, Partnership, CHUV, Pharmaceutical industry, Nursing, Flour

RaySearch and MedAustron expand their partnership through a new strategic research agreement.

Key Points: 
  • RaySearch and MedAustron expand their partnership through a new strategic research agreement.
  • RaySearch's business partner IBA has placed an order for RayStation and RayCare for installation at CRO National Cancer Institute (C.R.O.)
  • RaySearch has received an order from Israel-based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

InterAx Biotech Announces the Appointment of Seasoned Pharmaceutical Executive, Mark Levick, MD, Ph.D. as New Board Director

Retrieved on: 
Tuesday, October 3, 2023
Research, Technology, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Artificial Intelligence, Faculty, GSK, Royal college, University, Drug development, Senior, Tropical medicine, G protein-coupled receptor, Levick, University of Cambridge, Membership of the Royal College of Physicians of Ireland, Cancer, ETH Zurich, Faculty of Pharmaceutical Medicine, Multimedia, Biomarker, Computational chemistry, Doctor of Philosophy, Language, Paul Scherrer Institute, GPCR, Novartis, MD, Vivo, Drug discovery, Commonwealth Scholarship and Fellowship Plan, Artificial intelligence, Marie Cassidy, FRCPA, University of Newcastle, Pharmaceutical medicine, Pharmacology, Medical device, Pharmaceutical industry, EU, Physician, AI

InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.

Key Points: 
  • InterAx Biotech AG, a product development company pioneering computational pharmacology for creating breakthrough therapies, announces the appointment of Dr. Mark Levick to the board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20231003682932/en/
    Dr. Mark Levick, MD, Newly appointed Board Director of InterAx Biotech (Photo: Business Wire)
    Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ.
  • In addition to building the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
  • Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

Paul Scherrer Institute selects RayStation

Retrieved on: 
Monday, October 2, 2023
PSI, RaySearch Laboratories, Paul Scherrer Institute, Indiana University Health Proton Therapy Center, Cancer, Partnership, Research, Proton therapy, Medical imaging

STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations. PSI is equipped with three gantries and a fixed horizontal beam line room for ocular treatments. Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.

Key Points: 
  • STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- Renowned worldwide for its treatment of cancers with proton therapy, PSI has selected RayStation as the treatment planning system for its clinical operations.
  • Two of the gantries, of which one is in-house developed, operate clinically while the third is dedicated to research.
  • Alongside the procurement of RayStation, RaySearch and PSI have the intent of engaging in a collaborative research initiative.
  • Damien C. Weber, Chairman of the proton Therapy Center, Paul Scherrer Institute, says: "By combining proton therapy with advanced treatment planning system as proposed by RaySearch, we can push the boundaries of optimal cancer care.

ITM Enters Cooperation Agreement with Paul Scherrer Institute (PSI) for Co-Development and Upscaled Manufacturing of Terbium-161 for Theranostic Application in Cancer

Retrieved on: 
Thursday, April 27, 2023
ITM, Therapy, Research group, TRT, PSI, Cancer, Auger, Research, Radiopharmaceutical, Doctor of Philosophy, Paul Scherrer Institute, Hospital, Patient, TRT1, Actinium-225, Pharmaceutical industry, Medical imaging

The partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.

Key Points: 
  • The partners will combine their respective technologies and expertise in the production of terbium-161 including clinical and commercial use in Targeted Radionuclide Therapy (TRT) for the treatment of cancer.
  • This collaboration significantly expands ITM’s production and development portfolio for medical isotopes in precision oncology.
  • Terbium-161 has been identified as a very promising therapeutic isotope for TRT1 in cancer based on its outstanding physico-chemical properties.
  • Terbium-161’s potential as a next-generation radioisotope is based on its unique ability to emit both medium-range beta radiation and short-range Auger electrons.

Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer

Retrieved on: 
Wednesday, October 12, 2022
Serono, Doctor of Philosophy, Therapeutic index, BIT, HSG, Hoffmann-La Roche, Pharmacy, MBA, Paul Scherrer Institute, Technology, University, Jaden Philogene-Bidace, Turin, Business development, ADC, Innovation, GLOBE, ETH Zurich, Head, University of St. Gallen, PSI, FDA, Hotel manager, Control, Fine chemical, Chemistry

AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.

Key Points: 
  • AU ZH, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer.
  • We are thrilled to welcome Filippo to our executive team, said Philipp Spycher, Ph.D., chief executive officer of Araris Biotech.
  • Araris stands to make an impact in the ADC space and I am honored to be a part of the company.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.

Apollo Health Ventures and Paul Scherrer Institute Launch Focal Biosciences

Retrieved on: 
Tuesday, October 11, 2022
Health, Genetics, Other Health, Managed Care, General Health, Pharmaceutical, Biotechnology, Time, Swiss Federal Institute of Aquatic Science and Technology, Science, Materials science, WSL, Laboratory, Patient, Biology, Research, Paul Scherrer Institute, Glossary, Swiss Federal Laboratories for Materials Science and Technology, Investment, CHF, Dysfunction, Snow, Glossary of genetics, Health, Degenerative disease, ETH Domain, ETH Zurich, Bessemer Venture Partners, Environment, PSI, Swiss Federal Institute for Forest, Snow and Landscape Research, Ageing, Aquatic science, Swiss Federal Institute of Technology, Engineering, Pharmaceutical industry, Technology, Swiss

Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences.

Key Points: 
  • Apollo Health Ventures and the Paul Scherrer Institute (PSI) launched Focal Biosciences.
  • Apollo Health Ventures and the Paul Scherrer Institute will join their resources together with scientific founder Prof. G.V.
  • Shivashankar, Scientific Founder of Focal Biosciences, Head of the Laboratory of Nanoscale Biology, Paul Scherrer Institute and Professor of Mechano-Genomics, ETH Zurich.
  • Apollo Health Ventures is a transatlantic venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures.

Araris Biotech Closes $24 Million Financing Round

Retrieved on: 
Tuesday, October 4, 2022
Cancer, ADC, Therapeutic index, PSI, Technology, Industry, FDA, Partner, Institute, ETH Zurich, Patient, Control, Follicular lymphoma, Paul Scherrer Institute, GLOBE, Fine chemical

ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (Araris or the Company), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.

Key Points: 
  • ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (Araris or the Company), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.
  • Proceeds from the financing will be used to support the further development and advancement of Araris antibody-drug conjugate (ADC) candidates, created using the Companys proprietary linker technology, as Araris moves closer towards clinical development.
  • Having invested in Araris seed round, we are now delighted to co-lead the latest round to ensure that Araris can unlock the potential of its differentiated technology and bring highly effective therapies to patients across the world.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.

Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit

Retrieved on: 
Wednesday, September 21, 2022
Control, Engineering, Paul Scherrer Institute, ADC, FDA, PSI, Antibody, Therapy, Technology, Therapeutic index, ETH Zurich, GLOBE, Fine chemical

ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the companys chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect.

Key Points: 
  • ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the companys chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect.
  • The presentation will highlight Araris proprietary linker technology, which enables the conjugation of various potent drug payloads to native off-the-shelf antibodies in a single step without the need for further engineering.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.
  • The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs.

Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022

Retrieved on: 
Wednesday, August 31, 2022
Conference, EV, ADC, ETH Zurich, Technology, Paul Scherrer Institute, GLOBE, Control, PSI, Plasma, FDA, Therapeutic index, Fine chemical

AU ZH, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris linker technology at the 13th Annual World ADC Conference in San Diego.

Key Points: 
  • AU ZH, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris linker technology at the 13th Annual World ADC Conference in San Diego.
  • The poster presentation, titled, "Inducing complete and long-lasting tumor eradications of a nectin-4 ADC generated with a novel linker technology, will be given on September 7, 2022, at 5:45 p.m. PT during the conferences scientific poster session.
  • Araris Biotech AG is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs.
  • The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs.